Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

University of California San Francisco (UCSF)

Status and phase: Not yet enrolling; Phase 4

Conditions: Atopic Dermatitis; Psoriasis

Treatments: Drug: Calcipotriene; Drug: Baractinib; Drug: Ixekizumab; Drug: Chloroquine; Device: In situ cutaneous microdevice; Drug: Adalimumab; Drug: Deucravacitinib; Drug: Crisaborole; Drug: Ruxolitinib; Drug: Tildrakizumab; Drug: Roflumilast; Drug: Certolizumab; Drug: Abrocitinib; Drug: Cyclosporine; Drug: Nemolizumab; Drug: Lebrikizumab; Drug: Infliximab; Drug: Apremilast; Drug: Bimekizumab; Drug: Secukinumab; Drug: 5-Fluorouracil; Drug: Methotrexate; Drug: Triamcinolone; Drug: Guselkumab; Drug: Tapinarof; Drug: Etanercept; Drug: Mycophenolate; Drug: Dupilumab; Drug: Risankizumab; Drug: Hydroxychloroquine; Drug: Upadacitinib; Drug: Tacrolimus; Drug: Tofacitinib; Drug: Tralokinumab; Drug: Azathioprine; Drug: Ustekinumab

Study type: Interventional

Funder types: Other

Identifiers

NCT07352566

25-43621

Details and patient eligibility

About

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

> 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral contraceptive pills or intrauterine device for at least 30 days)

Exclusion Criteria: None

Trial design

Primary purpose: Device Feasibility

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

In situ cutaneous microdevice

Experimental group

Description:

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Treatment:

Drug: Ustekinumab

Drug: Azathioprine

Drug: Tralokinumab

Drug: Tofacitinib

Drug: Upadacitinib

Drug: Tacrolimus

Drug: Hydroxychloroquine

Drug: Dupilumab

Drug: Mycophenolate

Drug: Risankizumab

Drug: Etanercept

Drug: Guselkumab

Drug: Tapinarof

Drug: Methotrexate

Drug: Triamcinolone

Drug: 5-Fluorouracil

Drug: Secukinumab

Drug: Bimekizumab

Drug: Apremilast

Drug: Infliximab

Drug: Lebrikizumab

Drug: Nemolizumab

Drug: Cyclosporine

Drug: Abrocitinib

Drug: Certolizumab

Drug: Roflumilast

Drug: Tildrakizumab

Drug: Ruxolitinib

Drug: Crisaborole

Drug: Deucravacitinib

Drug: Adalimumab

Drug: Chloroquine

Device: In situ cutaneous microdevice

Drug: Ixekizumab

Drug: Baractinib

Drug: Calcipotriene